NoCamels News Flash

Tagged: Chief Scientist RSS Toggle Comment Threads | Keyboard Shortcuts

• 

  NoCamels Team 1:21 pm on May 14, 2013 Permalink | Reply
  Tags: BioTime ( 3 ), cell cure ( 2 ), Chief Scientist, grant ( 8 ), opregen   

  Cell Cure Neurosciences Receives $1.33M Grant From Chief Scientist 

  Israeli biotech company Cell Cure Neurosciences, a subsidiary of biotech giant BioTime, has announced that it has received a $1.33 million grant from The Israeli Chief Scientist Office.

  The company says that it will use the funds to finance the development of its latest product, OpRegen, a cell-based treatment for macular degeneration, an age-related condition that impairs vision. The company has also announced that it will apply for human trials of the treatment this year.

   

  Reply Cancel reply

  Required fields are marked *

  Name *

  Email *

  Website

  

  Notify me of follow-up comments by email.

  Notify me of new posts by email.

• 

  NoCamels Team 11:23 am on October 30, 2012 Permalink | Reply
  Tags: Chief Scientist, funding ( 79 ), israel ( 51 ), seed stage companies   

  Israeli Government Allocates NIS 120M For Seed-Stage Companies 

  The Israeli Office of the Chief Scientist has received NIS 120 million (Approx. $30.7 million) from the Israeli treasury, which will be directed mostly towards investments in seed-stage companies in need of funding. The Chief Scientist was promised a total of NIS 400 million in 2012, but budgetary problems may prevent the entire sum to be delivered. So far, the treasury has transferred a total of NIS 300 million in 2012.

   
• 

  NoCamels Team 1:48 pm on August 1, 2012 Permalink | Reply
  Tags: BioTime ( 3 ), Cell Cure Neurosciences, Chief Scientist, grant ( 8 ), macular degeneration   

  ‘Cell Cure’ Granted $1.3M From Israel’s Chief Scientist Office 

  BioTime announced that its subsidiary Cell Cure Neurosciences has been awarded a grant of 5 million NIS (approximately $1.33 million) from Israel’s Office of the Chief Scientist. The funds will help finance the development of OpRegen(R), a cell-based therapeutic product for the treatment of age-related macular degeneration – a severe form of acute vision loss and the leading cause of blindness in an aging population. Cell Cure, established in 2005 is located in Jerusalem, Israel on the campus of Hadassah University Hospital.

   
• 

  NoCamels Team 2:14 pm on June 14, 2012 Permalink | Reply
  Tags: ALS ( 2 ), BrainStorm ( 3 ), Chief Scientist, grant ( 8 ), neurodegenerative disease   

  ‘BrainStorm’ Receives $1.1M Grant From Israel’s Chief Scientist 

  BrainStorm Cell Therapeutics, a developer of adult stem cell therapeutics targeting Central Nervous System (CNS) neurodegenerative diseases, announced today that the company received a grant of approximately $1.1 million from Israel’s Office of the Chief Scientist. The grant is awarded to towards the development of BrainStorm’s NurOwn therapy for the neurodegenerative disease ALS – also known as Lou Gehrig’s Disease – using adult stem cells. The treatment is currently under clinical trials in Israel, with interim results expected by July 2012.

   
• 

  NoCamels Team 11:27 am on May 9, 2012 Permalink | Reply
  Tags: Chief Scientist, grant ( 8 ), oral insulin capsule, Oramed ( 2 )   

  ‘Oramed’ Awarded Chief Scientist Of Israel Grant 

  Oramed Pharmaceuticals, a developer of oral delivery solutions for drugs and vaccines, announced that its wholly owned Israeli subsidiary, Oramed Ltd., was awarded a government grant amounting to a net sum of NIS 2 million (approximately $540,000), from the Office of the Chief Scientist. The funds will be used to support further R&D and clinical studies on its oral insulin capsule. Founded in 2006, Oramed’s corporate and R&D headquarters are based in Jerusalem, Israel.

   
• 

  NoCamels Team 10:00 am on May 3, 2012 Permalink | Reply
  Tags: Chief Scientist, funding ( 79 ), israel ( 51 ), startups ( 7 ), VC ( 36 )   

  Israel’s Chief Scientist Aims To Establish Governmental VC Fund 

  Israel’s Chief Scientist, Avi Hasson, announced that he is holding extensive talks with the Ministry of Finance to establish a governmental VC fund that will invest in early-stage startups. According to Hasson, his request from the Ministry of Finance is an annual budget of 100 million Shekels (approximately $26.4 million) for the investment in startups having difficulties to raise initial VC. He added that these companies are expected to enjoy long-term investments and will receive the Chief Scientist’s approval prior to the funding.